Targets › GUCY2C
8 programs from 7 companies in 9 trials: 6 Phase 1, 2 Phase 2, 1 Phase 4; Oncology, Other, Metabolic and endocrine; next expected readout Nov 2026.
Guanylyl cyclase that catalyzes synthesis of cyclic GMP (cGMP) from GTP. Receptor for the E.coli heat-stable enterotoxin; E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GUCY2C. Also activated by the endogenous peptides guanylin and uroguanylin. (UniProt, P25092)
Open in Phaseline: the race on GUCY2C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Texas Tech University Health Sciences Center, El Paso | linaclotide Heat-stable enterotoxin receptor agonist | GUCY2C | Phase 4 | Chronic Constipation | Jan 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Linaclotide Heat-stable enterotoxin receptor agonist | GUCY2C | Phase 2 | Colorectal Adenoma | Nov 2026 |
| Bausch Health Americas | plecanatide Heat-stable enterotoxin receptor agonist | GUCY2C | Phase 2 | Functional Constipation (FC) | Oct 2027 |
| Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H | CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15 | Phase 1 | Colorectal Cancer; Colorectal Cancer Metastatic | Mar 2027 |
| Thomas Jefferson University | Ad5.F35-hGUCY2C-PADRE vaccine Adenovirus 5 vector expressing human GUCY2C antigen with PADRE epitope for cancer immunoth | GUCY2C | Phase 1 | Colorectal Cancer | Oct 2027 |
| Thomas Jefferson University | Lm-GUCY2C vaccine Recombinant Listeria monocytogenes expressing human GUCY2C antigen for cancer immunotherap | GUCY2C | Phase 1 | Colorectal Cancer | Oct 2027 |
| Second Affiliated Hospital of Guangzhou Medical University | Mesothelin/GPC3/GUCY2C-CAR-T cells CAR-T cells targeting mesothelin, GPC3, and GUCY2C; second generation with IL-21/anti-PD-1 | MSLN, GPC3, GUCY2C | Phase 1 | Pancreas Cancer | Mar 2029 |
| University of Florida | Linaclotide Heat-stable enterotoxin receptor agonist | GUCY2C | Phase 1 | Patients Scheduled for Colonoscopy | – |
Colorectal Cancer (3) Colorectal Cancer Metastatic (1) Colorectal Adenoma (1) Patients Scheduled for Colonoscopy (1) Chronic Constipation (1) Functional Constipation (FC) (1) Pancreas Cancer (1)
other (3), protein or peptide (3), mixed (1), small molecule (1)
Thomas Jefferson University (2) Beijing Biotech (1) Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) University of Florida (1) Texas Tech University Health Sciences Center, El Paso (1) Bausch Health Americas (1) Second Affiliated Hospital of Guangzhou Medical University (1)
CEACAM5 (1) ERBB2 (1) CEA (1) HER2 (1) IL15 (1) MSLN (1) GPC3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.